Journals / Türk Onkoloji Dergisi / 2020 / Cilt: 35 - Sayı: 1

Alteration in Characteristics and Outcome of Pediatric Burkitt Lymphoma in Turkey: Single-center Experience

Pages
58–63
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We think that the intra-abdominal component is seen more in our geography withtime, but it should be evaluated with more studies in other geographies, especially in Europe and America.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVEBurkitt Lymphoma (BL) is an aggressive and rapidly progressive form of non-Hodgkin’s lymphomas(NHL), and BL gives rise to 3-4% of all childhood malignancies.
📊
Key Findings & Data:Its event-free survival has increased upto 85% with current treatment protocols.
💡
Conclusion & Impact:We think that the intra-abdominal component is seen more in our geography withtime, but it should be evaluated with more studies in other geographies, especially in Europe and America.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVEBurkitt Lymphoma (BL) is an aggressive and rapidly progressive form of non-Hodgkin’s lymphomas(NHL), and BL gives rise to 3-4% of all childhood malignancies. Its event-free survival has increased upto 85% with current treatment protocols. In this study, we aimed to investigate whether there are somealterations of the clinical and laboratory features of BL at our center in Turkey before and now, or not.METHODSWe gathered medical records of a total of 101 patients with BL who were treated in our center retrospectively and assessed for laboratory findings, clinical characteristics, prognostic factors and treatmentprotocols.RESULTSWe found that, nowadays, intra-abdominal presentation of BL was seen more frequently than past at ourcenter in Turkey. However, there was no statistically significant difference. BL was numerically meaningful. Murphy’s treatment protocol was more satisfactory compared to past treatment protocols.CONCLUSIONOur comparison of the previous and present features of patients showed that there is a shift away from thejaw to mostly intra-abdominal disease presentation at our center, like Uganda, in the course of time. Andwe also have a large number of patients and the follow-up period is very long (median 111 months for allpatients) in the literature. We think that the intra-abdominal component is seen more in our geography withtime, but it should be evaluated with more studies in other geographies, especially in Europe and America.

🔖

Cite This Article

BOZKURT, C., YÜKSEK, N., ŞAHİN, G., ÖZDEMİR, S. İ., BALKAYA, E. (2022). Alteration in Characteristics and Outcome of Pediatric Burkitt Lymphoma in Turkey: Single-center Experience. Türk Onkoloji Dergisi, Cilt: 35 - Sayı: 1, 58–63. https://ajindex.com/articles/639174

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Miles RR, Arnold S, Cairo MS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/ leukaemia. Br J Haematol 2012;156(6):730−43
  2. Ferry JA. Burkitt’s Lymphoma: Clinicopathologic Features and Differential Diagnosis. Oncologist 2006;11(4):375−83
  3. Leoncini L, Raphael M, Stein H, Harris NL, Jaffe ES, Kluin PM. Burkitt Lymphoma. In; Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Lyon, France: IARC Press, 2008.p. 262−4
  4. Hudson MM, Onciu M, and Donaldson SS. Hodgkin lymphoma. In: Pizzo PA, Poplack DG editors. Principles, and Practice of Pediatric Oncology, 7th ed. Philedelphia: Lipincott Williams & Wilkins, 2011. p. 722−36
  5. Lanzkowsky P. Manuel of Pediatric Hematology and Oncology, 4th edition. Elsevier, 2005.p. 491−511,777,786
  6. Robertson ES. Burkitt lymphoma. New York: Springer; 2013. p. 81−131
  7. Wright DH, Addis BJ, Leong ASY. Diagnostic Lymph Node Pathology, 2nd edition. CRC Press, 2011. p. 85−6
  8. Cairo MS, Sposto R, Perkins SL, Meadows AT, HooverRegan ML, Anderson JR, et al. Burkitt’s and Burkitt like lymphoma in children and adolescents: a review of the Children’s Cancer Group experience. Br J Haematol 2003;120(4):660−70
  9. Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM. Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer 2008;123(11):2658−63. 10.Al-Attar A, Pritchard J, Al-Saleem T, Al-Naimi M, Alash N, Attra A. Intensive chemotherapy for non-localised Burkitt’s lymphoma. Arch Dis Child 1986;61(10):1013−9. 11.Murphy SB, Bowman WP, Abromowitch M, Mirro J, Ochs J, Rivera G, et al. Results of treatment of advanced-stage Burkitt’s lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high- -dose methotrexate and cytarabine. J Clin Oncol 1986;4(12):1732−9. 12.Cunha KC, Oliveira MC, Gomes AC, de Castro LP, Viana MB. Clinical course and prognostic factors of children with Burkitt’s lymphoma in a developing country: the experience of a single centre in Brazil. Rev Bras Hematol Hemoter 2012;34(5):361−6. 13.Ertem U, Duru F, Pamir A, Taçyildiz N, Dağdemir A, Akçayöz A, et al. Burkitt’s Lymphoma in 63 Turkish Children Diagnosed Over a 10 Year Period. Pediatric Hematology and Oncology 1996;13(2):123−34. 14.Tınaztepe B, Göğüş S, Tınaztepe S. Burkitt lenfoma: Hacettepe Çocuk Hastanesind